A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION (FXS6837-I-102)
AN OPEN-LABEL, PARALLEL-GROUP CLINICAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES FOLLOWING A SINGLE DOSE IN PARTICIPANTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT AND PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Approximately 24 participants with hepatic impairment and participants with normal hepatic function are planned to be enrolled into this study. Participants will undergo screening examinations from D-28 to D-1. Eligible participants will be admitted to the clinical study site on D-1. During the trial, participants will undergo laboratory tests, 12-lead ECG, vital sign observation, AE collection, and PK, PD, and plasma protein binding (PPB) sample collection.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female, aged 18-70 years (both inclusive), at screening;
-
Weight ≥ 50 kg and ≤ 120.0 kg for males, weight ≥ 45 kg and ≤ 120.0 kg for females, and body mass index (BMI) 18.0-35.0 kg/m2 (both inclusive), at screening;
-
Subject is eligible to enter the study if:
- matched control subject: physical examination, vital signs, laboratory tests (hematology, serum chemistry, urinalysis, coagulation function, etc.), 12-lead ECG, abdomen ultrasound, and chest X-ray judged by the investigator to be normal or abnormal without clinical significance;
- Subject with mild or moderate hepatic impairment:Chronic hepatic impairment caused by primary liver diseases: this condition is defined as patients with a prior diagnosis of hepatic impairment whose liver function is assessed by the investigator to have been stable for ≥ 3 months on the basis of clinical manifestations, with Child-Pugh Class A/mild (5-6 points) or Class B/moderate (7-9 points).
Exclusion Criteria:
-
Patients with serious diseases of cardiovascular, respiratory, digestive, endocrine, renal, hematological, or neurological/psychiatric systems within 1 year prior to screening;
-
Positive T-SPOT test results during the screening period, considered to indicate active tuberculosis based on the participant's clinical symptoms, chest X-ray, and laboratory tests;
-
History of meningococcal infection, or history of meningococcal infection in first-degree relatives; Or confirmed history of infection with encapsulated microorganisms within 6 months prior to screening, including but not limited to Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae;
-
History of known or suspected immunodeficiency, hereditary or acquired complement deficiency; Or current use of immunosuppressants;
-
Pregnant or lactating women or those with positive pregnancy test results;
-
Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:
- Drug-induced liver injury;
- History of liver transplantation;
- Presence of serious ascites or pleural effusion requiring puncture drainage;
- Hepatorenal syndrome;
- Diseases affecting biliary excretion, such as biliary cirrhosis, biliary obstruction, and cholestatic liver disease, within 3 months prior to screening;
- Serious portal hypertension rendering the patient unsuitable for participating in the study as assessed by the investigator;
- History of portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt;
- Current liver failure or complicated with Grade 2-4 hepatic encephalopathy;
- Suspected or confirmed liver cancer;
- Cirrhosis with complications such as esophageal or gastric variceal bleeding, spontaneous peritonitis, etc., that the investigator considers unsuitable for participation in the study, within 3 months prior to screening;
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Mild hepatic impairment
Arm 1:mild hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
実験的:Moderate hepatic impairment
Arm 2: moderate hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
実験的:Normal hepatic function
Arm 3: normal hepatic function FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:Cmax
時間枠:Up to Day 14
|
Maximum observed concentration (Cmax) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-t
時間枠:Up to Day 14
|
Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-∞
時間枠:Up to Day 14
|
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) |
Up to Day 14
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary PK parameter of FXS6837 in plasma: Tmax
時間枠:Up to Day 14
|
Time to reach maximum concentration(Tmax) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: t1/2
時間枠:Up to Day 14
|
Half-life (t1/2) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: CL/F
時間枠:Up to Day 14
|
Apparent total plasma clearance (CL/F) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: Vz/F
時間枠:Up to Day 14
|
Apparent terminal volume of distribution (Vz/F) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: Cmax,u
時間枠:Up to Day 14
|
Maximum unbound concentration (Cmax, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-t, u
時間枠:Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to time t (AUC0-t, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-∞, u
時間枠:Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to infinity (AUC0-∞, u) |
Up to Day 14
|
|
Incidence and severity of AE and SAE
時間枠:Up to Day 14
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), including abnormalities in clinical symptoms and vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests |
Up to Day 14
|
|
Pharmacodynamics indicator of FXS6837. Change from baseline in peripheral blood complement Alternative Pathway activity
時間枠:Up to Day 5
|
Complement alternative pathway (AP) activity in peripheral blood.Complement alternative pathway (AP) activity will be measured in peripheral blood. Absolute change and percentage change from baseline to Day 5 will be assessed. |
Up to Day 5
|
協力者と研究者
スポンサー
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- FXS6837-I-102
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。